[The Petri Dish] India raises the bar on patentability of pharmaceuticals
[MGCC Perspectives] Compulsory Licensing for Pharmaceutical Products
[The Petri Dish] Compulsory Licensing for Pharmaceutical Products
[The Petri Dish] New Development on Patent Protection on Medical Methods
India Raises The Bar On Patentability Of Pharmaceuticals
In the much awaited decision of the Supreme Court of India in the case of Novartis AG vs. Union of India and others, the Supreme Court upheld the decision of the Indian Patent Office which refused to grant a patent on the beta crystalline form of the imatinib mesylatechemical compound, a therapeutic drug for chronic myeloid […]
Amendments To Diovan Patent Claims Allowed
A recent decision in the High Court of Singapore involved yet another dispute in the pharmaceutical industry between an innovator giant and a generic manufacturer. This time, the case refers to a patent litigation battle between Switzerland-based Novartis and its exclusive licensee in Singapore (the Plaintiffs), and Ranbaxy (M) Sdn Bhd (the Defendant). On the […]
[ITMA Review] Malaysia’s Year in Mark
No Bones About It – Why Artril is Too Similar to Viartril
As pharmaceutical companies constantly work to develop new products, there are sure to be multiple drugs – either already available or in various stages of trials and testing – to alleviate any given ailment or the symptoms thereof. These companies rely heavily on IP law to ensure that their product and reputation remain unharmed by […]
[MGCC Quarterly] CSR and Intellectual Property
Ban On Stem Cell Patenting – Big Mistake In The Making?
Malaysia, being one of the fast developing countries, has been showing keen interest in stem cell research and therapy. As the awareness in stem cell technology increases, issues like morals and ethics have been raised by various parties such as religious bodies and conservative organizations. These controversies do not only occur in Malaysia but also […]